Drug Profile
Research programme: Alzheimer's disease therapeutics - CoPlex Therapeutics/Hawthorn Pharmaceuticals
Alternative Names: haw AD14Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CoPlex Therapeutics
- Developer Hawthorn Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 13 Sep 2011 Preclinical trials in Alzheimer's disease in USA (PO)